Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aflibercept + verteporfin
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravitreal, Intravenous
01
Overview
A combination therapy consisting of intravitreal aflibercept injection (anti-VEGF agent) and verteporfin photodynamic therapy (PDT). This dual approach targets different aspects of retinal vascular diseases - aflibercept inhibits VEGF to reduce abnormal blood vessel growth and leakage, while PDT with verteporfin selectively damages abnormal blood vessels through light activation of the photosensitizer. The combination is primarily used for treating polypoidal choroidal vasculopathy (PCV) and neovascular age-related macular degeneration (AMD).
02
Targets
LGALS1 (Galectin-1)PGF (Placental Growth Factor)Membrane lipids/proteins in choroidal neovascular tissueVEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)
Beyond the preview
Go deeper on aflibercept + verteporfin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aflibercept + verteporfin.